Does tirzepatide prevent doxorubicin-induced cardiotoxicity in preclinical models?
Tirzepatide demonstrates protective effects against doxorubicin-induced cardiotoxicity in preclinical models via the HRD1/Nrf2 pathway.
Our study suggested that TZP attenuated oxidative stress and cardiomyocyte apoptosis by modulating HRD1-mediated Nrf2 expression and activity, thereby protecting against the cardiotoxic effects exerted by DOX. These results supported that TZP might be a promising therapeutic option for reducing chemotherapy-related cardiotoxicity.
Yang et al. (Thu,) studied this question.